Paroxetine (Paxil, Seroxat): Increased risk of suicide in pediatric patients

CMAJ. Canadian Medical Association Journal

Volumn 169, Issue 5, 2003, Pages 446-

  Wooltorton, Eric ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PAROXETINE;

ANXIETY DISORDER; ARTICLE; CHILD; DRUG SAFETY; HUMAN; MAJOR DEPRESSION; OBSESSIVE COMPULSIVE DISORDER; PEDIATRICS; SUICIDAL BEHAVIOR; SUICIDE; SUICIDE ATTEMPT;

EID: 0041385736     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Remick RA. Diagnosis and management of depression in primary care: a clinical update and review [review]. CMAJ 2002;167(11):1253-60.
2. Hazell P. Depression in children and adolescents [review]. Am Fam Physician 2003;67(3):577-9.
3. Son SE, Kirchner JT. Depression in children and adolescents. Am Fam Physician 2000;62(10):2297-308, 2311-2.
4. Ryan ND. Medication treatment for depression in children and adolescents. CNS Spectr 2003;8:283-7.
5. Important drug warning: Until further information is available, Paxil® (paroxetine hydrochloride) should not be used in children and adolescents under 18 years of age [Dear Health Care Professional Letter]. Mississauga (ON): GlaxoSmithKline Inc.; July 2003. Available: www.hc-sc.gc.ca/hpfb-dgpsa/rpd-dpt/paxil_e.html (accessed 2003 Aug 5).
6. Paxil [product monograph]. In: Compendium of pharmaceuticals and specialties. Ottawa: Canadian Pharmacists Association; 2003. p. 1255-60.
7. Green B. Focus on paroxetine. Curr Med Res Opin 2003;19(1):13-21.